NAUT — Nautilus Biotechnology Balance Sheet
0.000.00%
Last trade - 00:00- $355.75m
- $174.39m
- 45
- 36
- 46
- 38
Annual balance sheet for Nautilus Biotechnology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 16.7 | 76.7 | 346 | 184 | 173 |
| Prepaid Expenses | |||||
| Total Current Assets | 17 | 77.7 | 349 | 187 | 177 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1.12 | 6.21 | 31.9 | 32.6 | 36.9 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 18.5 | 85 | 398 | 350 | 306 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.49 | 3.02 | 5.81 | 6.79 | 9.12 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 0.49 | 6.31 | 34.9 | 35.1 | 40.2 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 18.1 | 78.7 | 364 | 315 | 265 |
| Total Liabilities & Shareholders' Equity | 18.5 | 85 | 398 | 350 | 306 |
| Total Common Shares Outstanding |